All Trials

A Randomized Phase II Study of Consolidative Surgery and Radiotherapy With Curative Intent for De Novo Oligometastatic HER2+ Breast Cancer [Ablation and Resection for the Consolidation of Oligometastatic HER2+ Breast Cancer (ARCHER)]

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with de novo oligometastatic (≤5 lesions), non-CNS, HER2-positive breast cancer with disease control after 3–12 months of first-line therapy (typically taxane plus trastuzumab/pertuzumab, HER2-targeted mAbs) are randomized to continue systemic therapy alone versus adding consolidative local therapy with curative intent (breast surgery, locoregional RT, and SBRT to all metastases) while continuing standard HER2-directed therapy. Primary endpoint: progression-free survival.

ClinicalTrials.gov ID: NCT07053085

Randomized Phase II Trial of Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with symptomatic or progressive radioactive iodine–resistant differentiated thyroid cancer (papillary/follicular/Hürthle; ECOG 0–2; ≤1 prior VEGF/VEGFR therapy) are randomized to lenvatinib monotherapy starting at 24 mg/day versus 10 mg/day. Lenvatinib is a multikinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT; the study tests whether a lower starting dose improves tolerability without compromising antitumor activity.

ClinicalTrials.gov ID: NCT07092514

DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with stage IV, PD-L1–negative NSCLC without actionable drivers and detectable baseline ctDNA are randomized to standard chemo plus pembrolizumab versus chemo plus dual checkpoint blockade (nivolumab [PD-1] + ipilimumab [CTLA-4]), with maintenance per histology. Aims to assess early molecular response (ctDNA clearance by Cycle 4 Day 1) and key clinical outcomes; treated/stable CNS metastases allowed.

ClinicalTrials.gov ID: NCT06364917

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Untreated adults with locally advanced unresectable or metastatic non-squamous NSCLC that overexpresses HER2 and has PD-L1 TPS &lt;50%, without actionable driver alterations or HER2 mutation. Randomized to trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor) plus pembrolizumab versus standard pemetrexed/platinum plus pembrolizumab.

ClinicalTrials.gov ID: NCT06899126

Single-Arm, Prospective, Multicenter Study Evaluating Safety, Tolerability, and Metabolism of Niraparib as Maintenance Following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm maintenance study of oral niraparib (PARP inhibitor) in women ≥18 who self-identify as Black/African ancestry (including Afro-Latinas) with newly diagnosed FIGO III–IV high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer who achieved CR/PR to first-line platinum therapy. Enrolls patients with adequate organ function and no platinum-refractory disease to assess safety, tolerability, pharmacokinetics, and disease control during up to 24 cycles of niraparib.

ClinicalTrials.gov ID: NCT06412120

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma (ECOG 0–2) without prior pancreatic radiation receive stereotactic-like adaptive radiation therapy in 5 every-other-day fractions after optional induction chemotherapy. The trial escalates ART dose to biologically aggressive tumor regions while sparing organs-at-risk, with primary focus on grade ≥3 GI toxicity and secondary measures of local control and survival.

ClinicalTrials.gov ID: NCT06984562

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma who have disease control after 4–6 months of first-line chemotherapy (FOLFIRINOX/mFOLFIRINOX, NALIRIFOX, or gemcitabine/nab-paclitaxel) are randomized to standard post-induction management (continue chemo, standard-dose chemoradiation with 5-FU/capecitabine, or observation) versus dose‑escalated radiation (preferably 5 fractions; or 25 fractions with optional 5-FU/capecitabine), with chemotherapy completion to 6 months as needed. No investigational drugs are used; the trial tests whether higher-dose, precision RT improves survival.

ClinicalTrials.gov ID: NCT06958328

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic PDAC and cancer-associated cachexia (ECOG 0–1) beginning next cycle of first-line nab-paclitaxel/gemcitabine or (m)FOLFIRINOX are randomized to add ponsegromab, a subcutaneous anti–GDF-15 monoclonal antibody aimed at improving appetite/weight and function, versus placebo. Investigational therapy is given Q4W alongside standard chemotherapy; exclusions include reversible anorexia causes, CNS metastases, significant cardiac dysfunction, severe hepatic/renal impairment, and tube or parenteral feeding.

ClinicalTrials.gov ID: NCT06989437

A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with mCRPC harboring pathogenic HRR mutations (e.g., BRCA1/2, ATM [≤15%], CDK12, CHEK2, PALB2, etc.) after progression on abiraterone, castrate testosterone, and ECOG 0–1; excludes prior PARP inhibitors/platinum and prior ARPI for CRPC other than abiraterone. Randomizes to talazoparib (PARP1/2 inhibitor) plus enzalutamide (androgen receptor inhibitor) versus talazoparib alone.

ClinicalTrials.gov ID: NCT06844383

Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with de novo or metachronous high-volume metastatic castration-sensitive prostate adenocarcinoma (M1 on conventional imaging; no PSMA-PET–only or N1-only disease) are randomized to ADT plus apalutamide versus ADT plus apalutamide with docetaxel (up to 6 cycles). Apalutamide is a second‑generation androgen receptor antagonist; docetaxel is a microtubule-stabilizing taxane, and the trial tests whether adding docetaxel to the ADT+apalutamide backbone improves overall survival, including in genomically defined subgroups (TP53/PTEN/RB1).

ClinicalTrials.gov ID: NCT06931340